In contrast to DNAM-1, TIGIT is weakly expressed by naive T cells; in cancer, it is co-expressed with PD-1 on tumour antigen-specific CD8+ T cells and CD8+ tumour-infiltrating lymphocytes (TILs) in humans. Here, TIGIT is linked to neoplasm.